The first patent in its kind in the world
ToolGen’s CRISPR/Cas system employs CRISPR/Cas9 in eukaryotic cell, the first patent of its kind in the world (by the earliest application date).
In addition, ToolGen’s original patent covers expansive claims on the composition and cell application of CRISPR/Cas system for the purpose of utilizing genome editing.
ToolGen intends to grow together with diverse fields by licensing its CRISPR IP to them.
Therapeutics and Drug Discovery applications
Genome-edited plant and seed
Gene-engineering Research Tools
Cell Lines and Animal Models Development applications
CROs, CMO/CDMOs applications